**NSE/BSE Listed Entity** Indo Euro Indchem Limited (formerly known as **Rinku Polychem Limited**) is an Indian enterprise currently undergoing a fundamental strategic transformation. Historically a manufacturing-focused entity, the company is pivoting toward a capital-efficient model centered on the **international trading of specialized industrial commodities** and diversification into **high-growth healthcare and life sciences sectors**. --- ### Strategic Pivot: From Manufacturing to Global Trading The company has formally decided to **close down its manufacturing activities** to mitigate rising operational costs and regulatory pressures. This shift is driven by a need to remain competitive in a landscape defined by low-cost global competition and volatile raw material pricing. **Key Drivers for the Transition:** * **Infrastructure Constraints:** A critical lack of **water availability** at the **MIDC Osmanabad** site led to a "huge increase" in manufacturing costs, rendering internal production unviable. * **Environmental & Regulatory Pressure:** Increasingly **stricter environmental laws** and the high cost of compliance have prompted a move toward trading and distribution. * **Capital Efficiency:** By focusing on **Trading Operations** and **Export Market Expansion**, the company aims to reduce overhead and leverage global demand without the burden of heavy industrial assets. --- ### Core Business Segments & Product Portfolio The company currently operates under a **single business segment** focusing on the procurement and distribution of industrial raw materials sourced primarily from **Europe, Japan, and China**. | Segment | Key Products & Materials | | :--- | :--- | | **Chemicals** | **Pigments** and **Organic Chemicals** | | **Paper & Decor** | **Base Paper**, **Tissue Paper**, and **Laminates** | | **Industrial Supplies** | **Press Plates** and **Steel Plates** | | **Agri-Inputs** | **Poultry Feed** and related supplements | --- ### Future Growth: Diversification into Healthcare & Life Sciences In **September 2024**, the company passed special resolutions to alter its **Memorandum of Association (MoA)**, authorizing entry into several high-margin sectors. This expansion is intended to de-risk the business from industrial cycles. * **Pharmaceuticals & Healthcare:** Manufacturing, importing, and dealing in **chemical parental preparations**, **radium treatments**, and general pharmaceuticals. * **Medical Technology:** Fabrication and trading of **medical devices**, **surgical products**, and **scientific apparatus**, including the engineering of specialized healthcare environments. * **Advanced Pulp & Forestry:** Processing of **paper pulp, wood pulp, and synthetic pulp**, with plans to develop **forests and nurseries** for captive consumption. * **Chemical Diversification:** Expanding the trading basket to include **agro-chemicals, petrochemicals, polymers, resins, and gaseous materials**. --- ### Financial Performance & Capital Allocation The company has experienced a significant contraction in scale during the most recent fiscal cycle, leading to a conservative approach to liquidity. **Comparative Financial Summary:** | Metric | FY 2022-23 | FY 2021-22 | Change (%) | | :--- | :--- | :--- | :--- | | **Revenue from Operations** | **₹10.08 Crore** | **₹22.64 Crore** | **-55.48%** | | **Other Income** | **₹48.63 Lakh** | **₹23.53 Lakh** | **+106.67%** | | **Net Profit** | **₹21.69 Lakh** | **₹51.16 Lakh** | **-57.60%** | **Financial Management Notes:** * **Dividend Policy:** The Board did **not recommend a dividend** for the current year, opting to **conserve resources** for the proposed business expansion. * **Asset Management:** Management continues to pursue **overdue trade receivables** as of **February 2026**. Despite auditor concerns, the company has **not provided for doubtful debts**, viewing these amounts as fully recoverable. * **Inventory:** Valuation follows a consistent method with **timely management verification**. --- ### Governance & Leadership Structure The company is led by a long-standing management team, recently re-appointed to oversee the five-year strategic transition. * **Chairman & Managing Director:** **Vardhman Chhaganlal Shah** (Term: **Sept 2023 – Aug 2028**) * **Executive Director:** **Akshit B. Lakhani** (Term: **Sept 2023 – Aug 2028**) * **Registered Office:** B-9 to B-16, **M.I.D.C. Osmanabad - 413 501**, Maharashtra. --- ### Risk Profile & Compliance Challenges Investors should note several persistent regulatory and operational risks identified in recent audits. **1. Audit Qualifications & Financial Risks:** * **Unprovided Receivables:** Statutory Auditors have issued a **Qualified Opinion** regarding the lack of provisioning for **old, long-outstanding receivables**. * **Market Volatility:** High exposure to **Exchange rate fluctuations** and global economic slowdowns due to the import-heavy nature of the trading business. **2. Regulatory Non-Compliance Issues:** The company has faced observations regarding lapses in **Companies Act, 2013** and **SEBI (LODR)** regulations: * **Director Qualifications:** Certain **Independent Directors** failed to register in the mandatory **Independent Directors Databank** or pass the **Online Proficiency Test**. * **Filing Lapses:** Failure to file **e-Form MGT-14** (loans/resolutions), **Form MR-1** (executive appointments), and timely intimations to the **Stock Exchange** under **Regulation 30**. * **Transparency:** The company website was not updated with mandatory documents (Regulation 46) due to reported issues with the developer. * **Executive Remuneration:** Payments were made to the MD/ED without full compliance with **Section 197** and **Schedule V**. **3. Internal Control Remediation:** To address historical gaps, the company has appointed **M/s. Moxit & Associates** as **Internal Auditors** for the period ending **March 31, 2025**, and **M/s VKMG & Associates LLP** as **Secretarial Auditors** to oversee compliance corrections.